Clinical Experience of Kidney Transplantation in the Hallym University Hospital.
- Author:
Samuel LEE
1
;
Philip LEE
;
Ma Hae CHO
;
Joo Seop KIM
;
Young Cheol LEE
;
Dong Wan CHAE
;
Hyung Jik KIM
;
Dae Yul YANG
;
Sung Yong KIM
;
Ha Young KIM
;
Kyung Wha LEE
;
Hyoun Chan CHO
;
Eun Sook NAM
;
Mi Hae KIM
;
Soo Tae KIM
;
Dae Won YOON
;
Chang Sig CHOI
Author Information
1. Department of Surgery, College of Medicine, Hallym University, Korea.
- Publication Type:Original Article
- Keywords:
Kidney transplantation clinical results
- MeSH:
Allografts;
Antilymphocyte Serum;
Cadaver;
Diabetes Mellitus;
Female;
Follow-Up Studies;
Graft Survival;
Humans;
Immunosuppression;
Kidney Failure, Chronic;
Kidney Transplantation*;
Kidney*;
Living Donors;
Male;
Mortality;
Muromonab-CD3;
Tissue Donors;
Unrelated Donors
- From:The Journal of the Korean Society for Transplantation
1998;12(2):191-198
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Renal transplantation has been adopted as the treatment of choices for most patients with a end stage renal disease. This is the presentation of our experience of renal transplantation at Hallym University Hospital. From March 1984 to July 1998, 207 cases of renal transplantations were performed, 15 cases out of which were lost during follow-up period and excluded from the study. The mean age of recipients was 37.1 years. The male to female ratio was 1.5:1. Eighty nine renal allografts (46.4%) were from living unrelated donors, 59 (30.7%) from living donors and 44 (22.9%) from cadaveric donors. As an immunosuppression theray, a triple regimen was used in 104 cases (54.2), a double regimen in 86 (44.8%) and a single regimen in one (0.5%). The overall rejection developed in 87 cases (45.3%). The rejection rate was 59.3% in renal allografts from living related donors, 37.1% from living unrelated donors and 43.2% from cadavaric donors. The OKT3 and the antilymphocyte globulin (ALG) were used for steroid resistent rejection in 8 and 2 cases, respectively. Post-transplant diabetes mellitus were noticed in 22 cases (11.5). The most common complication was infection (28.1%), and 11 recipeints (5.7%) died during follw-up period. Infection was the leading cause of mortality. The overall graft survival was 92.2% at 1 year span and 83.1% at 3 year span. The overall patient survival was 95.6% at 1 year span and 92.5% at 3 year span.
